Law360, New York (February 09, 2012, 4:52 PM ET) -- The Federal Circuit on Thursday rejected AstraZeneca Pharmaceuticals LP's bid to bar generic versions of its cholesterol drug Crestor, finding it couldn't pursue infringement claims against generics makers that sought to promote the drug for uses not claimed in AstraZeneca's patents.
In affirming the dismissal of nine suits, a three-judge panel rejected AstraZeneca's contention that its claims were warranted because generic versions of Crestor would be prescribed for any possible condition even if regulators approved them for unpatented uses.
“[I]f accepted, these speculative arguments would allow...
AstraZeneca Can't Block Generic Crestor: Fed. Circ.
To view the full article, take a free trial now.
